Association Between Circulating Soluble Receptor for Advanced Glycation End Products (sRAGE) and Atherosclerosis: Observations from the Dallas Heart Study
- Jason B. Lindsey, MD1,
- James A. de Lemos, MD1,
- Francesco Cipollone, MD2,
- Colby R. Ayers, MS1,
- Anand Rohatgi, MD1,
- David A. Morrow, MD, MPH3,
- Amit Khera, MD, MSc1 and
- Darren K. McGuire, MD, MHSc (darren.mcguire{at}utsouthwestern.edu)1
- From the 1Donald W. Reynolds Cardiovascular Clinical Research Center, the University of Texas Southwestern Medical Center, Dallas, Texas
- 2Italian Society for the Study of Atherosclerosis-Abruzzo Section, Chieti, Italy; and the
- 3Brigham and Women's Hospital, Boston, Massachusetts
Abstract
Objective: To determine the association between circulating soluble RAGE (sRAGE) and coronary atherosclerosis.
Research Design and Methods: Using data from the Dallas Heart Study, a probability-based population sample, the association between plasma levels of sRAGE and coronary artery calcium (CAC) was assessed among 2571 subjects with complete imaging and sRAGE data.
Results: An inverse, graded association was observed between sRAGE quartiles and CAC, with CAC prevalence of 28.5% in quartile 1 compared with 15.7% in quartile 4 (p<0.0001). After multivariable adjustment, the associations between sRAGE levels in the 1st and 2nd quartiles (vs 4th quartile) and CAC remained statistically significant (adjusted OR 1.71, 95% CI 1.2 to 2.4; and 1.5, 95% CI 1.0 to 2.1, respectively).
Conclusions: sRAGE is a novel biomarker that is inversely associated with coronary atherosclerosis. The role of sRAGE in the pathobiology of atherosclerosis and its potential prognostic and therapeutic implications warrant further investigation.
Footnotes
-
- Received January 12, 2009.
- Accepted April 2, 2009.
- Copyright © American Diabetes Association
